Merck, Novo Nordisk spared from 1,500 suits over diabetes drug blamed for cancer

Novo Nordisk has been let off the hook in multiple lawsuits brought forth by diabetes patients in the US, alleging cancer links with some of Novo’s and also Merck’s diabetes treatments.

Photo: Novo Nordisk / PR

Consumers suing Merck & Co., Novo Nordisk A/S and other makers of diabetes drugs allegedly linked to pancreatic cancer are dropping their complaints, according to an email seen by Bloomberg.

The decision, revealed in an email to clients from an attorney involved in the litigation, will spare the company from facing more than 1,500 lawsuits. It comes after a judge last year barred the plaintiffs’ experts from testifying about any cancer link, a ruling that was upheld on appeal late last month.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs